Back

Real-world outcomes and safety of low- vs. standard-dose SGLT2 inhibitors in heart failure

30 August 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Heart failure therapies: current drug strategies Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Omri Braver

Toronto General Hospital, Toronto (Canada)

6 More presentations in this session

Presentation thumbnail
GLP-1 receptor agonists for obesity-related heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials
Mr C. Rodrigues Rosa (Belo Horizonte, BR)
Abstract Slides Video
Presentation thumbnail
Targeting the HIF-1/ASC pathway with dapagliflozin protects against sleep apnea-exacerbated myocardial damage in heart failure
Doctor L. Xie (Nanjing, CN)
Abstract Slides
Presentation thumbnail
Levosimendan in advanced heart failure: a step forward in functional recovery and hospitalization reduction
Doctor F. Gerardo (Amadora, PT)
Abstract Slides Video
Presentation thumbnail
Early exercise-based rehabilitation for patients with acute decompensated heart failure: an updated systematic review and meta-analysis
Mr D. Abraham (Manaus, BR)
Abstract Slides Video
Presentation thumbnail
SGLT2 inhibitor therapy in patients with acute Takotsubo syndrome
Doctor L. Arcari (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure therapies: current drug strategies

The Event

Event poster

ESC Congress 2025

30 August 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Early SGLT2i therapy in patients with T2DM and ACS results in reduction in cardiovascular and renal outcomes- a propensity score matched multi-model retrospective registry analysis
30 August 2025
thumbnail
Congress Presentation
Factors influencing the up-titration to 10 mg target dose of vericiguat: data from a large observational cohort-study in the US.
17 May 2025
thumbnail
Congress Presentation
Sodium-Glucose Co-Transporter 2 inhibitors and cardiovascular outcomes: a trial-similar population vs. a broad population
29 August 2025
thumbnail
Congress Presentation
Efficacy and safety of SGLT2 inhibitors in heart failure: real-world evidence in geriatric patients
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources